About 20,000 US women are diagnosed with ovarian cancer each year, most at an advanced stage. Surgery and platinum chemotherapy come first, often followed by PARP inhibitor or bevacizumab maintenance. When cancer becomes platinum-resistant, new antibody-drug conjugates and combinations are adding options.
- 1,139studies open or running
- 118phase 3 trials
- 4,622papers published this year
- 40NIH-funded projects
-
Now
Nov 2026
Immunotherapy finally extends survivalHappened 17.7 mo median survival
Pembrolizumab with paclitaxel: median survival 17.7 vs 14.0 months in platinum-resistant disease.
17.7 mo: median survival with pembrolizumab, vs 14.0.
Relacorilant approvedHappened
A cortisol-blocking pill with nab-paclitaxel was approved in March 2026 for platinum-resistant disease.
A targeted option for low-grade serousHappened 44% tumors shrank
Avutometinib plus defactinib shrank 44% of KRAS-mutated tumors.
44%: response rate in KRAS-mutated tumors.
-
6 months
by May 2027
Matching PARP drugs to the right patientsLikely
Final PRIMA results showed no overall survival gain, focusing PARP maintenance on BRCA and HRD tumors.
-
12 months
by Nov 2027
Mirvetuximab maintenance resultsPossible
GLORIOSA (520 people) tests adding mirvetuximab to bevacizumab maintenance; due April 2027.
-
3 years
by late 2029
Next-generation FRα drug conjugatesPossible
AstraZeneca's AZD5335 (1,100 people) and Lilly's sofetabart mipitecan (1,630) report around 2028.
HER2 drug in maintenancePossible
DO-01 tests trastuzumab deruxtecan with bevacizumab for HER2-expressing tumors; due November 2028.
-
5 years
by late 2031
How long PARP maintenance should lastPossible
An 880-person NRG trial compares 1 vs 2 years of olaparib, with or without bevacizumab.
The research paths
Antibody-drug conjugates
Details and 4 trialsHide
Targeted chemotherapy carriers aimed at FRα, HER2, CDH6 and B7-H4.
WatchGLORIOSA; next-generation FRα conjugates.
- Mirvetuximab with bevacizumab maintenance (GLORIOSA)AbbVie · 520 people · fully enrolled Apr 2027
- AZD5335 (TREVI-OC-01)AstraZeneca · 1,100 people · enrolling Nov 2028
- Sofetabart mipitecan (FRAmework-01)Eli Lilly · 1,630 people · enrolling Nov 2028
- Trastuzumab deruxtecan with bevacizumab (DO-01)Daiichi Sankyo · 582 people · enrolling Nov 2028
Immunotherapy and new combinations
17.7 mo median survivalDetailsHide
Pembrolizumab and relacorilant added to chemotherapy for platinum-resistant disease.
WatchUptake and follow-up.
PARP maintenance
Details and 1 trialsHide
Refining who benefits and for how long.
WatchNRG duration trial.
Borrowed from other cancers
From Melanoma, lung and other cancers
Pembrolizumab
Phase 3 positive
Immunotherapy that now extends survival in ovarian cancer with chemotherapy.
From Breast and stomach cancer
Trastuzumab deruxtecan
Phase 3
A HER2 drug conjugate tested in HER2-expressing ovarian cancer.
Open to join now
-
Platinum-resistant
AZD5335
Locations and eligibility → -
Platinum-resistant
Sofetabart mipitecan
Locations and eligibility → -
HER2-expressing, maintenance
Trastuzumab deruxtecan with bevacizumab
Locations and eligibility → -
After first treatment
Olaparib duration
Locations and eligibility →
See every recruiting Ovarian cancer trial →
When the trials finish
Completion dates the trials registered. Results usually follow 3 to 12 months later.
- Heating up
- Maturing
- Early
- Cooling
- Fully enrolled, waiting on results
- Still enrolling
What just happened
KEYNOTE-B96: survival 17.7 vs 14.0 months
The Lancet.
FDA approves relacorilant
With nab-paclitaxel, platinum-resistant.
Standard treatment today
- New diagnosisSurgery and carboplatin-paclitaxel, sometimes chemotherapy first.
- MaintenancePARP inhibitor (olaparib or niraparib) by BRCA/HRD status, with or without bevacizumab.
- Platinum-sensitive relapsePlatinum chemotherapy again, then maintenance.
- Platinum-resistantMirvetuximab (FRα-high), relacorilant with nab-paclitaxel, pembrolizumab with paclitaxel, or other chemotherapy with bevacizumab.
How to read this page, and sourcesHow to read this page, and sources
- Most results apply to high-grade serous ovarian cancer; rarer types (clear cell, mucinous, low-grade) behave differently.
- Forecasts are editorial judgments by Find a Trial, not predictions from sponsors or regulators.
See Ovarian cancer trials recruiting now →